We have seen how results of bavi in trials depend on which combination drug is used. Is it possible that bavi could be combined with a different drug (say a downstream immuno drug) or other to fight HCV?
In the previous post, Nagata went to Canada in 2013 and Brazil in 2014 (Keystone Symposia events..), talking exposure of Phosphatidylserine. Now, this Japanese based lab, is "ALL" about targeting phosphatidylserine. Shigekazu is the expert of "Interferon", just as Peregrine KOL Dmitry Gabrilovich is the expert of MDSC's.
I believe that Nagata knows very well that targeting flipped-PS, is far superior than interferon, or better yet, replace all combinations from Interferon to a PS Targeting based drug, such as Bavituximab.
Peregrine's Joe Shan already discussed that as well, from the prior post:
So whats new ?? Nothing... Nagata lab still fully concentrating on Phosphatidylserine, and who has all those patents for targeting flipped Phosphatidylserine ? Peregrine Pharmaceuticals
Douglas Green; Marie-Lise Gougeon; Michael Hengartner; H. Robert Horvitz; Marja Jäättelä; Adi Kimchi;Sharad Kumar; Sergio Lavandero; Richard A. Lockshin; Carlos Martínez; Shigekazu Nagata; Don Nicholson; Mauro Piacentini; Jun-Ying Yuan; Boris Zhivotovsky
..... so now we have Nagata, a big PS Targeting researcher with ties to ICDS, International Cell Death Society and maybe its just coincidence, but there seems to be much interest in various parts of the world and ICDS next meeting, in Iran Oct 14